111493-56-2

Usage

Contains a pyrazole ring

A five-membered heterocyclic ring with four carbon atoms and one nitrogen atom.

Contains a carboxylic acid group

A functional group with a carboxyl (-COOH) moiety.

Methyl group present

A small alkyl group consisting of one carbon atom bonded to three hydrogen atoms.

Phenylmethylthio group present

A functional group consisting of a phenyl ring (a six-membered aromatic ring with a methyl group) bonded to a sulfur atom.

Unique properties

The presence of the methyl and phenylmethylthio groups at specific positions on the pyrazole ring may give 1H-Pyrazole-4-carboxylic acid, 1-methyl-5-[(phenylmethyl)thio]- unique chemical and physical properties.

Potential applications

1H-Pyrazole-4-carboxylic acid, 1-methyl-5-[(phenylmethyl)thio]- may have potential applications in organic synthesis and pharmaceutical research, such as the development of new drugs or as a building block for the synthesis of other organic compounds.

Upstream product

• 150-60-7 dibenzyl disulphide 
• 31037-02-2 ethyl 5-amino-1-methyl-1H-pyrazole-4-carboxylate 

Downstream Products

• 868681-37-2 5-benzylthio-1-methylpyrazole-4-carbohydroxamic acid 

Relevant academic research and scientific papers

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease

5-Lipoxygenase activating protein (FLAP) inhibitors attenuate 5-lipoxygenase pathway activity and reduce the production of proinflammatory and vasoactive leukotrienes. As such, they are hypothesized to have therapeutic benefit for the treatment of diseases that involve chronic inflammation including coronary artery disease. Herein, we disclose the medicinal chemistry discovery and the early clinical development of the FLAP inhibitor AZD5718 (12). Multiparameter optimization included securing adequate potency in human whole blood, navigation away from Ames mutagenic amine fragments while balancing metabolic stability and PK properties allowing for clinically relevant exposures after oral dosing. The superior safety profile of AZD5718 compared to earlier frontrunner compounds allowed us to perform a phase 1 clinical study in which AZD5718 demonstrated a dose dependent and greater than 90% suppression of leukotriene production over 24 h. Currently, AZD5718 is evaluated in a phase 2a study for treatment of coronary artery disease.

PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS

The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.